Phase 2 MZL Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
CLLDLBCLMCL+3 more
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07259070
Recruiting
Phase 2
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
Marginal Zone Lymphoma (MZL)
Ruijin Hospital145 enrolled3 locationsNCT06793189
Recruiting
Phase 2
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
LymphomaMarginal Zone LymphomaMZL
Gottfried von Keudell, MD PhD33 enrolled1 locationNCT06510309
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University50 enrolled1 locationNCT07448324
Recruiting
Phase 2
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital of Soochow University23 enrolled1 locationNCT07372365
Recruiting
Phase 2
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Marginal Zone Lymphoma (MZL)
The First Affiliated Hospital with Nanjing Medical University169 enrolled1 locationNCT07208981
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
Marginal Zone Lymphoma (MZL)
Fei Li90 enrolled1 locationNCT06700798
Recruiting
Phase 2
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Marginal Zone Lymphoma (MZL)
Second Affiliated Hospital, School of Medicine, Zhejiang University51 enrolled18 locationsNCT07022223
Recruiting
Phase 2
Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL
Initial MZLUntreated MZLBTKi+1 more
Li Zhiming33 enrolled2 locationsNCT06985472